OREGON DRUG USE REVIEW / PHARMACY & THERAPEUTICS COMMITTEE

Thursday, April 7th, 2022 1:00 - 5:00 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Cat Livingston, MD; Tim Langford, PharmD; Robin Moody, MPH; Bill Origer, MD; Russ Huffman, PMHNP; Patrick DeMartino, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Amanda Parish, LCSW; Sarah Servid, PharmD; Megan Herink, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD; Deborah Weston, JD


(*) Provided verbal testimony
Written testimony: Posted to OSU Website
I. CALL TO ORDER

A. Roll Call & Introductions  
   - Called to order at approx. 1:02 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Approval of Agenda and February 2022 Minutes presented by Roger Citron  
   **ACTION:** Motion to approve, 2\(^{nd}\), all in favor
D. Department Update provided by Andrew Gibler, PharmD
E. Legislative Update provided by Dee Weston, JD

II. CONSENT AGENDA TOPICS

A. **Oncology Prior Authorization (PA) Updates**  
   **Recommendation:**  
   - Add: Kimmtrak\textsuperscript{®} (tebentafusp) to Table 1 in the Oncology Agents prior authorization (PA) criteria
B. **Orphan Drug Policy Updates**  
   **Recommendation:**  
   - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Enjaymo\textsuperscript{™} (sutimlimab-jome) based on FDA-approved labeling  
   **ACTION:** Motion to Approve, 2\(^{nd}\), all in favor

III. DUR NEW BUSINESS

A. **Citizenship Waived Medical (CWM) Coverage Update:** Sarah Servid, PharmD  
   **Recommendation:**  
   Implement PA criteria for drugs prescribed for patients with the CWM benefit, and update PA criteria with relevant diagnoses if emergency drug coverage is expanded to other conditions in the future  
   **ACTION:** Motion to approve, 2\(^{nd}\), all in favor with one abstention

B. **Prior Authorization Updates:** Sarah Servid, PharmD  
   a. **Botulinum Toxins PA Update**  
      **Recommendation:**  
      - Update PA criteria as proposed  
      **ACTION:** Motion to approve, 2\(^{nd}\), all in favor
   b. **Drugs for Non-Funded Conditions PA Update**  
      **Recommendation:**
IV. DUR OLD BUSINESS

A. Hepatitis C Direct-Acting Antivirals Policy Discussion
   
   **Policy Discussion:** Andrew Gibler, PharmD; Dee Weston, JD
   **Prior Authorization Update:** Megan Herink, PharmD
   
   **Public Comment:**
   Charlie Lovan, AbbVie; Stuart O’Brochta, Gilead; Amy Burns, AllCare CCO; Robin Traver, Umpqua Health CCO; Douglas Carr, Umpqua Health CCO; Kate Jelline, Ardon Health Specialty Pharmacy; Lorren Sandt, Caring Ambassadors Program; Andy Seaman, Central City Concern; Ann Thomas, OHA Public Health
   
   **Recommendations:**
   - Remove PA criteria and required case management for preferred DAA regimens for treatment-naïve patients with hepatitis C virus
   
   **ACTION:** Motion to Approve, 2nd, all in favor with one abstention
   
   - Continue to require PA for: retreatment of HCV; non-preferred DAAs; and for uses not FDA approve
   
   **ACTION:** Motion to Approve, 2nd, all in favor
   
   - Make sofosbuvir/velpatasvir/voxilaprevir (Vosevi®) non-preferred and continue to reserve it for treatment-experienced individuals
   
   **ACTION:** Motion to Approve, 2nd, all in favor

V. PREFERRED DRUG LIST NEW BUSINESS

A. Sickle Cell Disease Literature Scan: Kathy Sentena, PharmD
   
   **Recommendations:**
   - No Preferred Drug List (PDL) changes recommended based on the clinical evidence
   - Update PA criteria to include the expanded age indication for voxelotor
   - Evaluate costs in executive session
   
   **Public Comment:** Santries Booze, Global Blood Therapeutics
ACTION: The Committee recommended: removing baseline pain crisis from approval criteria #8 for voxelotor approval; reword question #6 in approval criteria to change “failure” of hydroxyurea to “has the patient received (or have contraindications to) a 3 month trial of hydroxyurea at stable doses and will treatment of hydroxyurea be maintained”; reword question #7 in renewal criteria to simply require documented improvement from baseline (similar to question #5); and add “in pain symptoms” to #5 of renewal criteria
Motion to approve, 2nd, all in favor

B. Fabry Disease Literature Scan: Deanna Moretz, PharmD
Recommendation:
- Revise PA criteria to reflect expanded indication for agalsidase beta
ACTION: Motion to approve, 2nd, all in favor

C. Voxzogo™ (vosoritide) New Drug Evaluation: David Engen, PharmD
Recommendation:
- Implement proposed PA criteria for vosoritide to ensure appropriate use
ACTION: Motion to approve, 2nd, all in favor

D. Vyvgart™ (efgartigimod alfa-cab) New Drug Evaluation: Kathy Sentena, PharmD
Recommendations:
- Designate efgartigimod as non-preferred on the PDL and subject to PA criteria
- Implement proposed PA criteria to ensure appropriate use
ACTION: Motion to approve, 2nd, all in favor

E. Fluoroquinolone Drug Class Update: Deanna Moretz, PharmD
Recommendations:
- Designate moxifloxacin as a preferred on the PDL
- Review drug costs in Executive Session
ACTION: Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Cat Livingston, MD; Tim Langford, PharmD; Bill Origer, MD; Russ Huffman, PMHNP; Patrick DeMartino, MD; Eddie Saito, PharmD; Robin Moody, MPH

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan
VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Sickle Cell Disease Literature Scan
   Recommendation: No PDL changes recommended
   ACTION: Motion to approve, 2nd, all in favor

B. Fluoroquinolone Drug Class Update
   Recommendations: No PDL changes recommended
   ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN